Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Dotinurad (Primary) ; Febuxostat
- Indications Hyperuricaemia
- Focus Registrational; Therapeutic Use
- Sponsors Mochida Pharmaceutical
- 21 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.